|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoffman HT, Karnell LH, Shah JP, Ariyan S,
Brown GS, Fee WE, Glass AG, Goepfert H, Ossoff RH and Fremgen AM:
Hypopharyngeal cancer patient care evaluation. Laryngoscope.
107:1005–1017. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bova R, Goh R, Poulson M and Coman WB:
Total pharyngolaryngectomy for squamous cell carcinoma of
hypopharynx: A review. Laryngoscope. 115:864–869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Godballe C, Jørgensen K, Hansen O and
Bastholt L: Hypopharyngeal cancer: Results of treatment based on
radiation therapy and salvage surgery. Laryngoscope. 112:834–838.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dikshit RP, Boffetta P, Bouchardy C,
Merletti F, Crosignani P, Cuchi T, Ardanaz E and Brennan P: Risk
factors for the development of second primary tumors among men
after laryngeal and hypopharyngeal carcinoma. Cancer.
103:2326–2333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anderson RG: The caveolae membrane system.
Annu Rev Biochem. 67:199–225. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamada E: The fine structure of the gall
bladder epithelium of the mouse. J Biophys Biochem Cytol.
1:445–458. 1955. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rothberg KG, Heuser JE, Donzell WC, Ying
YS, Glenney JR and Anderson RG: Caveolin, a protein component of
caveolae membrane coats. Cell. 68:673–682. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rothberg KG, Heuser JE, Donzell WC, Ying
YS, Glenney JR and Anderson RG: Caveolin, a protein component of
caveolae membrane coats. Cell. 68:673–682. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smart EJ, Graf GA, McNiven MA, Sessa WC,
Engelman JA, Scherer PE, Okamoto T and Lisanti MP: Caveolins,
liquid-ordered domains and signal transduction. Mol Cell Biol.
19:7289–7304. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pike LJ, Han X, Chung KN and Gross RW:
Lipid rafts are enriched in arachidonic acid and
plasmenylethanolamine and their composition is independent of
caveolin-1 expression: A quantitative electrospray ionization/mass
spectrometric analysis. Biochemistry. 41:2075–2088. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Orlandi PA and Fishman PH:
Filipin-dependent inhibition of cholera toxin: Evidence for toxin
internalization and activation through caveolae-like domains. J
Cell Biol. 141:905–915. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park SS, Kim JE, Kim YA, Kim YC and Kim
SW: Caveolin-1 is down-regulated and inversely correlated with HER2
and EGFR expression status in invasive ductal carcinoma of the
breast. Histopathology. 47:625–630. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen ST, Lin SY, Yeh KT, Kuo SJ, Chan WL,
Chu YP and Chang JG: Mutational, epigenetic and expressional
analyses of caveolin-1 gene in breast cancers. Int J Mol Med.
14:577–582. 2004.PubMed/NCBI
|
|
15
|
Wiechen K, Sers C, Agoulnik A, Arlt K,
Dietel M, Schlag PM and Schneider U: Down-regulation of caveolin-1,
a candidate tumor suppressor gene, in sarcomas. Am J Pathol.
158:833–839. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bélanger MM, Roussel E and Couet J:
Caveolin-1 is down-regulated in human lung carcinoma and acts as a
candidate tumor suppressor gene. Chest. 125(5 Suppl): 106S2004.
View Article : Google Scholar
|
|
17
|
Wiechen K, Diatchenko L, Agoulnik A,
Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M,
Schäfer R and Sers C: Caveolin-1 is down-regulated in human ovarian
carcinoma and acts as a candidate tumor suppressor gene. Am J
Pathol. 159:1635–1643. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Engelman JA, Wykoff CC, Yasuhara S, Song
KS, Okamoto T and Lisanti MP: Recombinant expression of caveolin-1
in oncogenically transformed cells abrogates anchorage-independent
growth. J Biol Chem. 272:16374–16381. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee SW, Reimer CL, Oh P, Campbell DB and
Schnitzer JE: Tumor cell growth inhibition by caveolin
re-expression in human breast cancer cells. Oncogene. 16:1391–1397.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bender FC, Reymond MA, Bron C and Quest
AF: Caveolin-1 levels are down-regulated in human colon tumors, and
ectopic expression of caveolin-1 in colon carcinoma cell lines
reduces cell tumorigenicity. Cancer Res. 60:5870–5878.
2000.PubMed/NCBI
|
|
21
|
Yang G, Truong LD, Wheeler TM and Thompson
TC: Caveolin-1 expression in clinically confined human prostate
cancer: A novel prognostic marker. Cancer Res. 59:5719–5723.
1999.PubMed/NCBI
|
|
22
|
Suzuoki M, Miyamoto M, Kato K, Hiraoka K,
Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh
T, et al: Impact of caveolin-1 expression on prognosis of
pancreatic ductal adenocarcinoma. Br J Cancer. 87:1140–1144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobin LH and Wittekind CH: TNM
lassification of head and neck carcinomaInternational Union Against
Cancer, TNM: Classification of Malignant Tumours. 1. 5th. Wiley;
New York, NY: pp. 17–50. 1997
|
|
24
|
Zhao T, Zhu MG and Huang ZY: Comparative
study of expression of oncogene protein products in lung cancer.
Chinese Journal of Cancer. 1:13–15. 1995.
|
|
25
|
Pike LJ: Rafts defined: A report on the
keystone symposium on lipid rafts and cell function. J Lipid Res.
47:1597–1598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang WL, Lee CT, Lee YC, Hwang TZ, Wang
CC, Hwang JC, Tai CM, Chang CY, Tsai SS, Wang CP, et al: Risk
factors for developing synchronous esophageal neoplasia in patients
with head and neck cancer. Head Neck. 33:77–81. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Egloff AM, Rothstein ME, Seethala R,
Siegfried JM, Grandis JR and Stabile LP: Cross-talk between
estrogen receptor and epidermal growth factor receptor in head and
neck squamous cell carcinoma. Clin Cancer Res. 15:6529–6540. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li L, Yang G, Ebara S, Satoh T, Nasu Y,
Timme TL, Ren C, Wang J, Tahir SA and Thompson TC: Caveolin-1
mediates testosterone-stimulated survival/clonal growth and
promotes metastatic activities in prostate cancer cells. Cancer
Res. 61:4386–4392. 2001.PubMed/NCBI
|
|
29
|
Lu ML, Schneider MC, Zheng Y, Zhang X and
Richie JP: Caveolin-1 interacts with androgen receptor. A positive
modulator of androgen receptor mediated transactivation. J Biol
Chem. 276:13442–13451. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sonveaux P, Martinive P, DeWever J, Batova
Z, Daneau G, Pelat M, Ghisdal P, Grégoire V, Dessy C, Balligand JL
and Feron O: Caveolin-1 expression is critical for vascular
endothelial growth factor-induced ischemic hindlimb
collateralization and nitric oxide-mediated angiogenesis. Circ Res.
95:154–161. 2004. View Article : Google Scholar : PubMed/NCBI
|
